Annovis Bio, Inc. (ANVS) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.12

From 52W high−76.27%

Volume1.20M

Market cap$51.64M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$1.12

From 52W high

−76.27%

Volume

1.20M

Market cap

$51.64M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.7x

P/E (TTM)

—

RSI (14)

58.1

MomentumView details →

1D Return

+11.01%

YTD Return

−65.03%

SummaryUpdated Jun 1, 2026

Annovis Bio, Inc. (NASDAQ:ANVS) is a clinical-stage biotechnology company founded in 2008 and headquartered in Berwyn, Pennsylvania. The company went public in January 2020 and focuses on developing novel drug treatments for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Annovis operates as a drug platform company, meaning it develops a portfolio of compounds that can potentially treat multiple neurological conditions through similar mechanisms of action.

Ask drillr about Annovis Bio, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.7x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

−12.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

1164.01%

ROA (TTM)

−224.73%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+12.25%

FCF YoY

−75.52%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+30.69%

EBITDA YoY

—

MomentumView details →

1D Return

+11.01%

YTD Return

−65.03%

1Y Return

−40.69%

RSI (14)

58.1

vs 50D SMA

−0.65%

vs 200D SMA

−35.91%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

2.95x

Quick Ratio

2.95x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.40

EPS Surprise

11.76%

Beats (12Q)

5/12

Next Q EPS Est

−$0.23

Avg Surprise (4Q)

−19.24%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−49.52M

Op. CF (TTM)

−43.34M

Next earningsNov 11, 2026 →

Latest newsMore news →

Annovis Bio announced a proposed underwritten public offering of common stock or pre-funded warrants, together with accompanying warrants.2h ago

Annovis Bio received a notice from the New York Stock Exchange that it no longer complies with continued listing standards because its average market capitalization over 30 consecutive trading days and its stockholders’ equity were each below $50 million.5d ago

Similar companies

iBio, Inc.IBIO Fortress Biotech, Inc.FBIOP Coeptis Therapeutics, Inc.COEP Alps Group IncALPS Pliant Therapeutics, Inc.PLRX Werewolf Therapeutics, Inc.HOWL Find similar companies →

Latest newsMore news →

Annovis Bio announced a proposed underwritten public offering of common stock or pre-funded warrants, together with accompanying warrants.2h ago Annovis Bio received a notice from the New York Stock Exchange that it no longer complies with continued listing standards because its average market capitalization over 30 consecutive trading days and its stockholders’ equity were each below $50 million.5d ago